Citi Maintains Buy Rating on DAMAI ENT; IP Business Remains Underexploited

Written by Emily J. Thompson, Senior Investment Analyst

010600%

01896+0.97%

03690-0.2%

Source: aastocks

Updated: Sep 23 2025

0mins

Source: aastocks

DAMAI ENT's New Entry Point: DAMAI ENT has introduced a ticket purchasing option on Taobao Instant Commerce, leveraging its access to 300 million monthly active users to enhance its ticketing business ahead of the National Day Golden Week holiday.
Future Growth Potential: Citi maintains a Buy rating for DAMAI ENT, highlighting potential new IP collaborations and the opening of a Chiikawa store in Shanghai, while noting that the company benefits from traffic support from Taobao without incurring channel fees, positioning it favorably against competitors like MAOYAN ENT.

01060

$0.92+Infinity%1D

Analyst Views on 01060

Wall Street analysts forecast 01060 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01060 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Analyst Rating

0 Buy

0 Hold

0 Sell

Current: 0.920

Low

Averages

High

Current: 0.920

Low

Averages

High

Goldman Sachs

Buy

maintain

Al Analysis

2025-11-19

Reason

Goldman Sachs

Price Target

Al Analysis

2025-11-19

maintain

Buy

Reason

The analyst rating from Goldman Sachs is maintained as a "Buy" despite a reduction in the target price from HKD 1.3 to HKD 1.17. The reasoning behind this rating includes the solid results reported by DAMAI ENT for 1HFY26 and the expectation that the company's expansion of licensing resources, particularly from Sanrio into retail and consumer markets, will drive strong growth in the next 6-12 months. However, concerns about the slowdown in the domestic ticketing business, increased investments in international markets, and the company's reliance on Japanese intellectual property amid Sino-Japanese tensions have contributed to stock price volatility.

Citi

maintain

2025-11-18

Reason

Citi

Price Target

2025-11-18

maintain

Reason

The analyst rating from Citi is based on the assessment that the delay of the two Japanese films will have a very limited negative impact on China's overall box office, as Japanese films contributed only 5% to the box office last year. The primary concern is related to market sentiment and investor worries about potential risks to MAOYAN ENT, particularly regarding the possible suspension of its key film "Demon Slayer" if geopolitical tensions escalate. Despite the negative sentiment surrounding the involvement of Japanese IP, the actual impact on DAMAI ENT is expected to be minimal. Consequently, Citi has set target prices for DAMAI ENT at HKD1.4 and for MAOYAN ENT at HKD9.3.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 01060

Unlock Now

Jefferies

maintain

$1.4

2025-11-07

Reason

Jefferies

Price Target

$1.4

2025-11-07

maintain

Reason

The analyst rating for DAMAI ENT (01060.HK) is maintained at "Buy" with a target price of HKD1.4 due to a positive profit alert for 1HFY26, where estimated earnings are expected to exceed RMB500 million, surpassing both market and Jefferies' forecasts. This growth is attributed to the strong performance of Alifish and a year-over-year reduction in investment losses, aided by an improved asset structure. Additionally, Jefferies anticipates that investment losses will decrease in 1HFY26, contributing to the better-than-expected results.

CICC

Buy

maintain

$1.32

2025-11-07

Reason

CICC

Price Target

$1.32

2025-11-07

maintain

Buy

Reason

The analyst rating for DAMAI ENT (01060.HK) is positive due to the company's issuance of a profit alert indicating a significant expected increase in net profit for 1HFY2026, projected to be no less than RMB500 million, which represents a year-on-year growth of approximately 48%. This positive outlook is attributed to the strong performance of the Alifish business, which has shown robust revenue and profit growth. Additionally, the presence of popular intellectual properties (IPs) such as Sanrio, Chiikawa, and Crayon Shin-chan is seen as a key driver of current revenue and profit. CICC has maintained its full-year revenue and profit forecasts for the company and has set a target price that implies a 40% upside from the current stock price, further supporting the positive rating.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Citi Maintains Buy Rating on DAMAI ENT; IP Business Remains Underexploited

Analyst Views on 01060

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Eli Lilly (LLY) Innovates with GLP-1 Drugs, Driving Growth

Nvidia and Microsoft: Top AI Investment Opportunities

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch